Gut Microbiome Dysbiosis in Patients with Pemphigus and Correlation with Pathogenic Autoantibodies
Abstract
:1. Introduction
2. Materials and Methods
2.1. Patient Recruitment and Grouping
2.2. Clinical Data and Sample Collection
2.3. DNA Extraction and 16S rRNA Gene Sequencing
2.4. Bioinformatics Prediction and Statistical Analysis
3. Results
3.1. Characteristics of the Study Population
3.2. The Composition of Microbiota Varied among the AP, PR, and HC Groups
3.3. Compared to HCs, Pemphigus Patients Exhibited an Altered Abundance of GM Taxa
3.4. Patients in the Active Stage Showed Significant Alterations in GM Abundance Compared to Those in the Remission Stage at the Species Level
3.5. The GM Was Found to Be Correlated with Clinical Indicators in Patients with Pemphigus
3.6. Predictive Functional Pathways of the Microbial Community Were Analyzed in Patients with Pemphigus and HCs
4. Discussion
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Schmidt, E.; Kasperkiewicz, M.; Joly, P. Pemphigus. Lancet 2019, 394, 882–894. [Google Scholar] [CrossRef] [PubMed]
- Joly, P.; Horwath, B.; Patsatsi, A.; Uzun, S.; Bech, R.; Beissert, S.; Bergman, R.; Bernard, P.; Borradori, L.; Caproni, M.; et al. Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV). J. Eur. Acad. Dermatol. Venereol. JEADV 2020, 34, 1900–1913. [Google Scholar] [CrossRef] [PubMed]
- Di Zenzo, G.; Amber, K.T.; Sayar, B.S.; Müller, E.J.; Borradori, L. Immune response in pemphigus and beyond: Progresses and emerging concepts. Semin. Immunopathol. 2016, 38, 57–74. [Google Scholar] [CrossRef] [PubMed]
- Takahashi, H.; Iriki, H.; Asahina, Y. T cell autoimmunity and immune regulation to desmoglein 3, a pemphigus autoantigen. J. Dermatol. 2023, 50, 112–123. [Google Scholar] [CrossRef] [PubMed]
- Pollmann, R.; Schmidt, T.; Eming, R.; Hertl, M. Pemphigus: A Comprehensive Review on Pathogenesis, Clinical Presentation and Novel Therapeutic Approaches. Clin. Rev. Allergy Immunol. 2018, 54, 1–25. [Google Scholar] [CrossRef]
- Yoshimura, K.; Ishii, N.; Hamada, T.; Abe, T.; Ono, F.; Hashikawa, K.; Fukuda, S.; Ohyama, B.; Koga, H.; Sogame, R.; et al. Clinical and immunological profiles in 17 Japanese patients with drug-induced pemphigus studied at Kurume University. Br. J. Dermatol. 2014, 171, 544–553. [Google Scholar] [CrossRef]
- Morell-Dubois, S.; Carpentier, O.; Cottencin, O.; Queyrel, V.; Hachulla, E.; Hatron, P.Y.; Delaporte, E. Stressful life events and pemphigus. Dermatology 2008, 216, 104–108. [Google Scholar] [CrossRef] [PubMed]
- Orion, E.; Matz, H.; Wolf, R. Pemphigus vulgaris induced by radiotherapy. J. Eur. Acad. Dermatol. Venereol. JEADV 2004, 18, 508–509. [Google Scholar] [CrossRef]
- Ruocco, E.; Ruocco, V.; Lo Schiavo, A.; Brunetti, G.; Wolf, R. Viruses and pemphigus: An intriguing never-ending story. Dermatology 2014, 229, 310–315. [Google Scholar] [CrossRef]
- Marfatia, Y.S.; Patel, S.; Makrandi, S.; Sharma, P. Human immunodeficiency virus and pemphigus vulgaris: An interesting association. Indian J. Dermatol. Venereol. Leprol. 2007, 73, 354–355. [Google Scholar] [CrossRef]
- Sagi, L.; Sherer, Y.; Trau, H.; Shoenfeld, Y. Pemphigus and infectious agents. Autoimmun. Rev. 2008, 8, 33–35. [Google Scholar] [CrossRef]
- Brenner, S.; Sasson, A.; Sharon, O. Pemphigus and infections. Clin. Dermatol. 2002, 20, 114–118. [Google Scholar] [CrossRef] [PubMed]
- Berg, G.; Rybakova, D.; Fischer, D.; Cernava, T.; Vergès, M.C.; Charles, T.; Chen, X.; Cocolin, L.; Eversole, K.; Corral, G.H.; et al. Microbiome definition re-visited: Old concepts and new challenges. Microbiome 2020, 8, 103. [Google Scholar] [CrossRef]
- Marchesi, J.R.; Adams, D.H.; Fava, F.; Hermes, G.D.; Hirschfield, G.M.; Hold, G.; Quraishi, M.N.; Kinross, J.; Smidt, H.; Tuohy, K.M.; et al. The gut microbiota and host health: A new clinical frontier. Gut 2016, 65, 330–339. [Google Scholar] [CrossRef]
- Martel, J.; Chang, S.H.; Ko, Y.F.; Hwang, T.L.; Young, J.D.; Ojcius, D.M. Gut barrier disruption and chronic disease. Trends Endocrinol. Metab. 2022, 33, 247–265. [Google Scholar] [CrossRef]
- Yuan, X.; Wang, R.; Han, B.; Sun, C.; Chen, R.; Wei, H.; Chen, L.; Du, H.; Li, G.; Yang, Y.; et al. Functional and metabolic alterations of gut microbiota in children with new-onset type 1 diabetes. Nat. Commun. 2022, 13, 6356. [Google Scholar] [CrossRef] [PubMed]
- Mena-Vázquez, N.; Ruiz-Limón, P.; Moreno-Indias, I.; Manrique-Arija, S.; Tinahones, F.J.; Fernández-Nebro, A. Expansion of Rare and Harmful Lineages is Associated with Established Rheumatoid Arthritis. J. Clin. Med. 2020, 9, 1044. [Google Scholar] [CrossRef]
- Chen, B.D.; Jia, X.M.; Xu, J.Y.; Zhao, L.D.; Ji, J.Y.; Wu, B.X.; Ma, Y.; Li, H.; Zuo, X.X.; Pan, W.Y.; et al. An Autoimmunogenic and Proinflammatory Profile Defined by the Gut Microbiota of Patients with Untreated Systemic Lupus Erythematosus. Arthritis Rheumatol. 2021, 73, 232–243. [Google Scholar] [CrossRef] [PubMed]
- Hidalgo-Cantabrana, C.; Gomez, J.; Delgado, S.; Requena-Lopez, S.; Queiro-Silva, R.; Margolles, A.; Coto, E.; Sanchez, B.; Coto-Segura, P. Gut microbiota dysbiosis in a cohort of patients with psoriasis. Br. J. Dermatol. 2019, 181, 1287–1295. [Google Scholar] [CrossRef]
- Bzioueche, H.; Simonyté Sjödin, K.; West, C.E.; Khemis, A.; Rocchi, S.; Passeron, T.; Tulic, M.K. Analysis of Matched Skin and Gut Microbiome of Patients with Vitiligo Reveals Deep Skin Dysbiosis: Link with Mitochondrial and Immune Changes. J. Investig. Dermatol. 2021, 141, 2280–2290. [Google Scholar] [CrossRef]
- Hu, X.; Wu, Q.; Fan, Y.; Guo, F.; Li, S.; Zhang, S.; Zuo, Y.G. Identification of gut microbiota dysbiosis in bullous pemphigoid under different disease activity. Exp. Dermatol. 2023, 32, 2149–2159. [Google Scholar] [CrossRef] [PubMed]
- Moreno-Arrones, O.M.; Serrano-Villar, S.; Perez-Brocal, V.; Saceda-Corralo, D.; Morales-Raya, C.; Rodrigues-Barata, R.; Moya, A.; Jaen-Olasolo, P.; Vano-Galvan, S. Analysis of the gut microbiota in alopecia areata: Identification of bacterial biomarkers. J. Eur. Acad. Dermatol. Venereol. JEADV 2020, 34, 400–405. [Google Scholar] [CrossRef] [PubMed]
- Mahmud, M.R.; Akter, S.; Tamanna, S.K.; Mazumder, L.; Esti, I.Z.; Banerjee, S.; Akter, S.; Hasan, M.R.; Acharjee, M.; Hossain, M.S.; et al. Impact of gut microbiome on skin health: Gut-skin axis observed through the lenses of therapeutics and skin diseases. Gut Microbes 2022, 14, 2096995. [Google Scholar] [CrossRef] [PubMed]
- Huang, S.; Mao, J.; Zhou, L.; Xiong, X.; Deng, Y. The imbalance of gut microbiota and its correlation with plasma inflammatory cytokines in pemphigus vulgaris patients. Scand. J. Immunol. 2019, 90, e12799. [Google Scholar] [CrossRef] [PubMed]
- Scaglione, G.L.; Fania, L.; De Paolis, E.; De Bonis, M.; Mazzanti, C.; Di Zenzo, G.; Lechiancole, S.; Messinese, S.; Capoluongo, E. Evaluation of cutaneous, oral and intestinal microbiota in patients affected by pemphigus and bullous pemphigoid: A pilot study. Exp. Mol. Pathol. 2020, 112, 104331. [Google Scholar] [CrossRef] [PubMed]
- Wang, Y.; Xia, X.; Zhou, X.; Zhan, T.; Dai, Q.; Zhang, Y.; Zhang, W.; Shu, Y.; Li, W.; Xu, H. Association of gut microbiome and metabolites with onset and treatment response of patients with pemphigus vulgaris. Front. Immunol. 2023, 14, 1114586. [Google Scholar] [CrossRef] [PubMed]
- Guo, Z.; Yiu, N.; Hu, Z.; Zhou, W.; Long, X.; Yang, M.; Liao, J.; Zhang, G.; Lu, Q.; Zhao, M. Alterations of fecal microbiome and metabolome in pemphigus patients. J. Autoimmun. 2023, 141, 103108. [Google Scholar] [CrossRef] [PubMed]
- Murrell, D.F.; Peña, S.; Joly, P.; Marinovic, B.; Hashimoto, T.; Diaz, L.A.; Sinha, A.A.; Payne, A.S.; Daneshpazhooh, M.; Eming, R.; et al. Diagnosis and management of pemphigus: Recommendations of an international panel of experts. J. Am. Acad. Dermatol. 2020, 82, 575–585. [Google Scholar] [CrossRef]
- Zhang, C.; Zhang, M.; Wang, S.; Han, R.; Cao, Y.; Hua, W.; Mao, Y.; Zhang, X.; Pang, X.; Wei, C.; et al. Interactions between gut microbiota, host genetics and diet relevant to development of metabolic syndromes in mice. ISME J. 2010, 4, 232–241. [Google Scholar] [CrossRef]
- Zhang, Q.; Wu, Y.; Wang, J.; Wu, G.; Long, W.; Xue, Z.; Wang, L.; Zhang, X.; Pang, X.; Zhao, Y.; et al. Accelerated dysbiosis of gut microbiota during aggravation of DSS-induced colitis by a butyrate-producing bacterium. Sci. Rep. 2016, 6, 27572. [Google Scholar] [CrossRef]
- Liu, Y.X.; Qin, Y.; Chen, T.; Lu, M.; Qian, X.; Guo, X.; Bai, Y. A practical guide to amplicon and metagenomic analysis of microbiome data. Protein Cell 2021, 12, 315–330. [Google Scholar] [CrossRef] [PubMed]
- Rognes, T.; Flouri, T.; Nichols, B.; Quince, C.; Mahé, F. VSEARCH: A versatile open source tool for metagenomics. PeerJ 2016, 4, e2584. [Google Scholar] [CrossRef] [PubMed]
- Khan, T.J.; Ahmed, Y.M.; Zamzami, M.A.; Mohamed, S.A.; Khan, I.; Baothman, O.A.S.; Mehanna, M.G.; Yasir, M. Effect of atorvastatin on the gut microbiota of high fat diet-induced hypercholesterolemic rats. Sci. Rep. 2018, 8, 662. [Google Scholar] [CrossRef] [PubMed]
- Robinson, M.D.; McCarthy, D.J.; Smyth, G.K. edgeR: A Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 2010, 26, 139–140. [Google Scholar] [CrossRef] [PubMed]
- Douglas, G.M.; Maffei, V.J.; Zaneveld, J.R.; Yurgel, S.N.; Brown, J.R.; Taylor, C.M.; Huttenhower, C.; Langille, M.G.I. PICRUSt2 for prediction of metagenome functions. Nat. Biotechnol. 2020, 38, 685–688. [Google Scholar] [CrossRef] [PubMed]
- Franzosa, E.A.; Sirota-Madi, A.; Avila-Pacheco, J.; Fornelos, N.; Haiser, H.J.; Reinker, S.; Vatanen, T.; Hall, A.B.; Mallick, H.; McIver, L.J.; et al. Gut microbiome structure and metabolic activity in inflammatory bowel disease. Nat. Microbiol. 2019, 4, 293–305. [Google Scholar] [CrossRef] [PubMed]
- Toumi, E.; Goutorbe, B.; Plauzolles, A.; Bonnet, M.; Mezouar, S.; Militello, M.; Mege, J.L.; Chiche, L.; Halfon, P. Gut microbiota in systemic lupus erythematosus patients and lupus mouse model: A cross species comparative analysis for biomarker discovery. Front. Immunol. 2022, 13, 943241. [Google Scholar] [CrossRef] [PubMed]
- Tejesvi, M.V.; Arvonen, M.; Kangas, S.M.; Keskitalo, P.L.; Pirttilä, A.M.; Karttunen, T.J.; Vähäsalo, P. Faecal microbiome in new-onset juvenile idiopathic arthritis. Eur. J. Clin. Microbiol. Infect. Dis. 2016, 35, 363–370. [Google Scholar] [CrossRef] [PubMed]
- Ishaq, H.M.; Mohammad, I.S.; Shahzad, M.; Ma, C.; Raza, M.A.; Wu, X.; Guo, H.; Shi, P.; Xu, J. Molecular Alteration Analysis of Human Gut Microbial Composition in Graves’ disease Patients. Int. J. Biol. Sci. 2018, 14, 1558–1570. [Google Scholar] [CrossRef]
- Wang, H.; Li, Y.; Feng, X.; Li, Y.; Wang, W.; Qiu, C.; Xu, J.; Yang, Z.; Li, Z.; Zhou, Q.; et al. Dysfunctional gut microbiota and relative co-abundance network in infantile eczema. Gut Pathog. 2016, 8, 36. [Google Scholar] [CrossRef]
- Wei, Y.; Li, Y.; Yan, L.; Sun, C.; Miao, Q.; Wang, Q.; Xiao, X.; Lian, M.; Li, B.; Chen, Y.; et al. Alterations of gut microbiome in autoimmune hepatitis. Gut 2020, 69, 569–577. [Google Scholar] [CrossRef] [PubMed]
- Leiva-Gea, I.; Sánchez-Alcoholado, L.; Martín-Tejedor, B.; Castellano-Castillo, D.; Moreno-Indias, I.; Urda-Cardona, A.; Tinahones, F.J.; Fernández-García, J.C.; Queipo-Ortuño, M.I. Gut Microbiota Differs in Composition and Functionality between Children with Type 1 Diabetes and MODY2 and Healthy Control Subjects: A Case-Control Study. Diabetes Care 2018, 41, 2385–2395. [Google Scholar] [CrossRef] [PubMed]
- Huang, L.; Gao, R.; Yu, N.; Zhu, Y.; Ding, Y.; Qin, H. Dysbiosis of gut microbiota was closely associated with psoriasis. Sci. China Life Sci. 2019, 62, 807–815. [Google Scholar] [CrossRef] [PubMed]
- Arrieta, M.C.; Stiemsma, L.T.; Dimitriu, P.A.; Thorson, L.; Russell, S.; Yurist-Doutsch, S.; Kuzeljevic, B.; Gold, M.J.; Britton, H.M.; Lefebvre, D.L.; et al. Early infancy microbial and metabolic alterations affect risk of childhood asthma. Sci. Transl. Med. 2015, 7, 307ra152. [Google Scholar] [CrossRef] [PubMed]
- Alpizar-Rodriguez, D.; Lesker, T.R.; Gronow, A.; Gilbert, B.; Raemy, E.; Lamacchia, C.; Gabay, C.; Finckh, A.; Strowig, T. Prevotella copri in individuals at risk for rheumatoid arthritis. Ann. Rheum. Dis. 2019, 78, 590–593. [Google Scholar] [CrossRef] [PubMed]
- Elsherbiny, N.M.; Rammadan, M.; Hassan, E.A.; Ali, M.E.; El-Rehim, A.S.A.; Abbas, W.A.; Abozaid, M.A.A.; Hassanin, E.; Hetta, H.F. Autoimmune Hepatitis: Shifts in Gut Microbiota and Metabolic Pathways among Egyptian Patients. Microorganisms 2020, 8, 1011. [Google Scholar] [CrossRef] [PubMed]
- Bellone, M.; Brevi, A.; Huber, S. Microbiota-Propelled T Helper 17 Cells in Inflammatory Diseases and Cancer. Microbiol. Mol. Biol. Rev. 2020, 84, e00064-19. [Google Scholar] [CrossRef] [PubMed]
- Topi, S.; Bottalico, L.; Charitos, I.A.; Colella, M.; Di Domenico, M.; Palmirotta, R.; Santacroce, L. Biomolecular Mechanisms of Autoimmune Diseases and Their Relationship with the Resident Microbiota: Friend or Foe? Pathophysiology 2022, 29, 507–536. [Google Scholar] [CrossRef]
- Cosorich, I.; Dalla-Costa, G.; Sorini, C.; Ferrarese, R.; Messina, M.J.; Dolpady, J.; Radice, E.; Mariani, A.; Testoni, P.A.; Canducci, F.; et al. High frequency of intestinal T(H)17 cells correlates with microbiota alterations and disease activity in multiple sclerosis. Sci. Adv. 2017, 3, e1700492. [Google Scholar] [CrossRef]
- Tett, A.; Pasolli, E.; Masetti, G.; Ercolini, D.; Segata, N. Prevotella diversity, niches and interactions with the human host. Nat. Rev. Microbiol. 2021, 19, 585–599. [Google Scholar] [CrossRef]
- Pianta, A.; Arvikar, S.; Strle, K.; Drouin, E.E.; Wang, Q.; Costello, C.E.; Steere, A.C. Evidence of the Immune Relevance of Prevotella copri, a Gut Microbe, in Patients with Rheumatoid Arthritis. Arthritis Rheumatol. 2017, 69, 964–975. [Google Scholar] [CrossRef]
- Chang, S.H.; Choi, Y. Gut dysbiosis in autoimmune diseases: Association with mortality. Front. Cell Infect. Microbiol. 2023, 13, 1157918. [Google Scholar] [CrossRef]
- Sokol, H.; Pigneur, B.; Watterlot, L.; Lakhdari, O.; Bermúdez-Humarán, L.G.; Gratadoux, J.J.; Blugeon, S.; Bridonneau, C.; Furet, J.P.; Corthier, G.; et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc. Natl. Acad. Sci. USA 2008, 105, 16731–16736. [Google Scholar] [CrossRef]
- Mizuno, M.; Noto, D.; Kaga, N.; Chiba, A.; Miyake, S. The dual role of short fatty acid chains in the pathogenesis of autoimmune disease models. PLoS ONE 2017, 12, e0173032. [Google Scholar] [CrossRef]
- López, P.; Gueimonde, M.; Margolles, A.; Suárez, A. Distinct Bifidobacterium strains drive different immune responses in vitro. Int. J. Food Microbiol. 2010, 138, 157–165. [Google Scholar] [CrossRef]
- Xu, Q.; Ni, J.J.; Han, B.X.; Yan, S.S.; Wei, X.T.; Feng, G.J.; Zhang, H.; Zhang, L.; Li, B.; Pei, Y.F. Causal Relationship between Gut Microbiota and Autoimmune Diseases: A Two-Sample Mendelian Randomization Study. Front. Immunol. 2021, 12, 746998. [Google Scholar] [CrossRef] [PubMed]
- Fang, X.; Li, F.J.; Hong, D.J. Potential Role of Akkermansia muciniphila in Parkinson’s Disease and Other Neurological/Autoimmune Diseases. Curr. Med. Sci. 2021, 41, 1172–1177. [Google Scholar] [CrossRef] [PubMed]
- Jin, Z.L.; Chen, X.C. Changes in intestinal florae and serum inflammation in rheumatoid arthritis rats and the effects of probiotics. Eur. Rev. Med. Pharmacol. Sci. 2020, 24, 11820–11826. [Google Scholar] [CrossRef] [PubMed]
- Konuma, T.; Kohara, C.; Watanabe, E.; Takahashi, S.; Ozawa, G.; Inomata, K.; Suzuki, K.; Mizukami, M.; Nagai, E.; Okabe, M.; et al. Impact of Intestinal Microbiota on Reconstitution of Circulating Monocyte, Dendritic Cell, and Natural Killer Cell Subsets in Adults Undergoing Single-Unit Cord Blood Transplantation. Biol. Blood Marrow Transplant. J. Am. Soc. Blood Marrow Transplant. 2020, 26, e292–e297. [Google Scholar] [CrossRef]
- Shapiro, J.; Cohen, N.A.; Shalev, V.; Uzan, A.; Koren, O.; Maharshak, N. Psoriatic patients have a distinct structural and functional fecal microbiota compared with controls. J. Dermatol. 2019, 46, 595–603. [Google Scholar] [CrossRef]
- Luo, Z.; Jin, Z.; Tao, X.; Wang, T.; Wei, P.; Zhu, C.; Wang, Z. Combined microbiome and metabolome analysis of gut microbiota and metabolite interactions in chronic spontaneous urticaria. Front. Cell Infect. Microbiol. 2022, 12, 1094737. [Google Scholar] [CrossRef] [PubMed]
- Song, G.; Gan, Q.; Qi, W.; Wang, Y.; Xu, M.; Li, Y. Fructose Stimulated Colonic Arginine and Proline Metabolism Dysbiosis, Altered Microbiota and Aggravated Intestinal Barrier Dysfunction in DSS-Induced Colitis Rats. Nutrients 2023, 15, 782. [Google Scholar] [CrossRef] [PubMed]
- Fu, L.; Fu, S.; Wang, C.; Xie, M.; Wang, Y. Yogurt-sourced probiotic bacteria alleviate shrimp tropomyosin-induced allergic mucosal disorders, potentially through microbiota and metabolism modifications. Allergol. Int. Off. J. Jpn. Soc. Allergol. 2019, 68, 506–514. [Google Scholar] [CrossRef] [PubMed]
- Cheng, B.; Zheng, H.; Wu, F.; Wu, J.; Liu, X.; Tang, C.; Lu, S.; Chen, Z.; Song, F.; Ruan, J.; et al. Metabolomics analysis of Danggui Sini decoction on treatment of collagen-induced arthritis in rats. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 2017, 1061–1062, 282–291. [Google Scholar] [CrossRef]
- Ghosh, T.S.; Shanahan, F.; O’Toole, P.W. The gut microbiome as a modulator of healthy ageing. Nat. Rev. Gastroenterol. Hepatol. 2022, 19, 565–584. [Google Scholar] [CrossRef]
AP Group † | PR Group ‡ | HCs Group § | p-Value | |
---|---|---|---|---|
(n = 20) | (n = 11) | (n = 47) | ||
Age, years | 52.80 ± 16.79 | 60.36 ± 12.31 | 62.62 ± 11.45 | 0.024 |
Female | 11 (55.00%) | 6 (54.55%) | 29 (61.70%) | 0.834 |
Anti-Dsg1 ¶ | 125.32 ± 55.15 | 76.91 ± 74.34 | NA †† | 0.064 |
Anti-Dsg3 ¶ | 82.95 ± 7996 | 78.27 ± 75.63 | NA | 0.620 |
Subtypes ‡‡ | ||||
PV | 15 (75.00%) | 7 (63.64%) | NA | |
PF | 2 (10.00%) | 0 | NA | |
PE | 2 (10.00%) | 3 (27.27%) | NA | |
PH | 1 (5.00%) | 1 (9.09%) | NA | |
Systemic therapy | ||||
Untreated | 9 (45.00%) | 0 | ||
Systemic corticosteroids | 5 (25.00%) | 7 (63.64%) | ||
Systemic immunosuppressants | 1 (5.00%) | 1 (9.09%) | ||
Systemic corticosteroids + immunosuppressants | 5 (25.00%) | 3 (27.27%) | ||
Dosage of systemic corticosteroids (prednisolone or equivalent) §§ | 33 ± 22.51 | 8.18 ± 3.18 | NA | 0.007 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Li, S.-Z.; Wu, Q.-Y.; Fan, Y.; Guo, F.; Hu, X.-M.; Zuo, Y.-G. Gut Microbiome Dysbiosis in Patients with Pemphigus and Correlation with Pathogenic Autoantibodies. Biomolecules 2024, 14, 880. https://doi.org/10.3390/biom14070880
Li S-Z, Wu Q-Y, Fan Y, Guo F, Hu X-M, Zuo Y-G. Gut Microbiome Dysbiosis in Patients with Pemphigus and Correlation with Pathogenic Autoantibodies. Biomolecules. 2024; 14(7):880. https://doi.org/10.3390/biom14070880
Chicago/Turabian StyleLi, Si-Zhe, Qing-Yang Wu, Yue Fan, Feng Guo, Xiao-Min Hu, and Ya-Gang Zuo. 2024. "Gut Microbiome Dysbiosis in Patients with Pemphigus and Correlation with Pathogenic Autoantibodies" Biomolecules 14, no. 7: 880. https://doi.org/10.3390/biom14070880